Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
Casadei-Gardini A, Rovesti G, Dadduzio V, Vivaldi C, Lai E, Lonardi S, Fornaro L, Pretta A, Zagonel V, Bernardini L, Astara G, D'Amico FE, Masi G, Rimini M, Scartozzi M, Cascinu S. Casadei-Gardini A, et al. Among authors: lai e. HPB (Oxford). 2021 Jun;23(6):915-920. doi: 10.1016/j.hpb.2020.09.024. Epub 2020 Nov 12. HPB (Oxford). 2021. PMID: 33191108 Free article.
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Lai E, et al. Crit Rev Oncol Hematol. 2021 Jan;157:103167. doi: 10.1016/j.critrevonc.2020.103167. Epub 2020 Nov 12. Crit Rev Oncol Hematol. 2021. PMID: 33271389 Review.
Immune Checkpoint Inhibitors in the Treatment of HCC.
Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Donisi C, et al. Among authors: lai e. Front Oncol. 2021 Jan 7;10:601240. doi: 10.3389/fonc.2020.601240. eCollection 2020. Front Oncol. 2021. PMID: 33585218 Free PMC article. Review.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Russano M, et al. Among authors: lai e. Cancer Immunol Immunother. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31. Cancer Immunol Immunother. 2022. PMID: 34462870 Free PMC article.
The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials.
Dubois M, Liscia N, Brunetti O, Ziranu P, Lai E, Argentiero A, Mazza E, Cascinu S, Silvestris N, Casadei-Gardini A, Scartozzi M. Dubois M, et al. Among authors: lai e. Crit Rev Oncol Hematol. 2022 May;173:103674. doi: 10.1016/j.critrevonc.2022.103674. Epub 2022 Mar 30. Crit Rev Oncol Hematol. 2022. PMID: 35364261 Review.
1,673 results